Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 285.79% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 285.79% year-over-year, with the annual reading at $1.2 million for FY2025, 285.79% up from the prior year.
  • Gains from Sales and Divestitures hit $1.2 million in Q4 2025 for Taysha Gene Therapies, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $1.2 million in Q2 2025 to a low of $17334.0 in Q1 2024.
  • Historically, Gains from Sales and Divestitures has averaged $477343.9 across 4 years, with a median of $289756.0 in 2022.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 93.65% in 2023 and later skyrocketed 5953.64% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $256481.0 in 2022, then crashed by 86.48% to $34671.0 in 2023, then surged by 831.7% to $323031.0 in 2024, then surged by 285.79% to $1.2 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for TSHA at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.